NCT06981637View on ClinicalTrials.gov

Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2029

Conditions
Advanced Soft Tissue Sarcoma
Interventions
DRUG

Pegylated liposomal doxorubicin

pegylated liposomal doxorubicin 40mg / m2 every 4 weeks for a maximum of 12 cycles.

Trial Locations (7)

Unknown

Chang Gung Memorial Hospital, Kaohsiung City

Kaohsiung Medical University Chung-Ho Memorial Hospital,, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Tri-Service General Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER